MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$390,978K
(-5.05%↓ Y/Y)
Income tax (expense)
benefit
-$2,071K
(26.77%↑ Y/Y)
Net loss before
income taxes
-$393,049K
(-4.81%↓ Y/Y)
Interest and other
income, net
$10,307K
(-49.16%↓ Y/Y)
Amtagvi
$220,024K
(112.45%↑ Y/Y)
Proleukin
$43,478K
(-28.14%↓ Y/Y)
Loss from operations
-$403,356K
(-2.04%↓ Y/Y)
Total revenue
$263,502K
(827.99%↑ Y/Y)
Total costs and
expenses
$666,858K
(19.22%↑ Y/Y)
Research and development
$300,270K
(6.35%↑ Y/Y)
Cost of sales
$173,184K
(39.67%↑ Y/Y)
Selling, general, and
administrative
$152,322K
(-0.45%↓ Y/Y)
Depreciation and
amortization
$35,939K
Restructuring charges
$5,143K
Back
Back
Income Statement
source: myfinsight.com
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)